Literature DB >> 9129484

Cornstarch regimens for nocturnal treatment of young adults with type I glycogen storage disease.

J I Wolfsdorf1, J F Crigler.   

Abstract

The goal of treatment of type I glycogen storage disease (GSD-I) is to prevent hypoglycemia and its biochemical consequences. In seven patients with GSD-I with a mean age of 19.5 y (range: 18.8-21.7 y), we compared the biochemical effects of isoenergetic amounts of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) given in random order on consecutive nights either as a single dose at 2100 (time 0) or as equally divided doses at 2100 and 0200. Over the 10-h period of observation there were significant regimen-by-time interactions for plasma glucose, serum insulin, and blood lactate concentrations. Mean time-averaged plasma glucose (5.8 +/- 0.5 compared with 4.9 +/- 0.9 mmol/L) and serum insulin (244 +/- 93 compared with 151 +/- 57 pmol/L) concentrations from 0 to 360 min were significantly higher after the single dose; blood lactate and serum fatty acid concentrations were not significantly different. At 360 min, mean plasma glucose (4.8 +/- 1.2 compared with 4.7 +/- 1.6 mmol/L) and serum insulin (138 +/- 76 compared with 136 +/- 116 pmol/L) concentrations were virtually identical. After a single dose, plasma glucose concentrations were > or = 3.9 mmol/L for 7 h in five of seven subjects; three subjects were treated for hypoglycemia after 7-9.5 h. With divided doses, plasma glucose concentrations were > or = 3.9 mmol/L for 9 h in six of seven subjects; hypoglycemia occurred at 6 h in one subject. A single dose (1.76 +/- 0.41 g/kg) of UCS at bedtime maintains plasma glucose concentrations > or = 3.9 mmol/L for > or = 7 h in most young adults with GSD-I.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129484     DOI: 10.1093/ajcn/65.5.1507

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  10 in total

1.  Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.

Authors:  Xiaoyan Luo; Gentzon Hall; Songtao Li; Andrew Bird; Peter J Lavin; Michelle P Winn; Alex R Kemper; Talmage T Brown; Dwight D Koeberl
Journal:  Mol Ther       Date:  2011-07-05       Impact factor: 11.454

2.  Continuous glucose monitoring in children with glycogen storage disease type I.

Authors:  E Hershkovitz; A Rachmel; H Ben-Zaken; M Phillip
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  Alternative nighttime nutrition regimens in glycogen storage disease type I: a controlled crossover study.

Authors:  Michel Hochuli; Emanuel Christ; Fabian Meienberg; Roger Lehmann; Jan Krützfeldt; Matthias R Baumgartner
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

4.  High Incidence of Serologic Markers of Inflammatory Bowel Disease in Asymptomatic Patients with Glycogen Storage Disease Type Ia.

Authors:  Nicole T Lawrence; Tayoot Chengsupanimit; Laurie M Brown; David A Weinstein
Journal:  JIMD Rep       Date:  2015-06-21

5.  Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib.

Authors:  Catherine E Correia; Kaustuv Bhattacharya; Philip J Lee; Jonathan J Shuster; Douglas W Theriaque; Meena N Shankar; G Peter A Smit; David A Weinstein
Journal:  Am J Clin Nutr       Date:  2008-11       Impact factor: 7.045

6.  Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib.

Authors:  M K Davis; P A Rufo; S F Polyak; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2008-01-05       Impact factor: 4.982

7.  A novel starch for the treatment of glycogen storage diseases.

Authors:  K Bhattacharya; R C Orton; X Qi; H Mundy; D W Morley; M P Champion; S Eaton; R F Tester; P J Lee
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

Review 8.  The health impact of nighttime eating: old and new perspectives.

Authors:  Amber W Kinsey; Michael J Ormsbee
Journal:  Nutrients       Date:  2015-04-09       Impact factor: 5.717

Review 9.  The Physiopathological Role of the Exchangers Belonging to the SLC37 Family.

Authors:  Anna Rita Cappello; Rosita Curcio; Rosamaria Lappano; Marcello Maggiolini; Vincenza Dolce
Journal:  Front Chem       Date:  2018-04-17       Impact factor: 5.221

10.  Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.

Authors:  Hye-Ri Kang; Monika Gjorgjieva; Stephanie N Smith; Elizabeth D Brooks; Zelin Chen; Shawn M Burgess; Randy J Chandler; Lauren R Waskowicz; Kylie M Grady; Songtao Li; Gilles Mithieux; Charles P Venditti; Fabienne Rajas; Dwight D Koeberl
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-11       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.